Nanatinostat

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Nanatinostat
DrugBank Accession Number
DB15419
Background

Nanatinostat is under investigation in clinical trial NCT00697879 (Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 394.41
Monoisotopic: 394.155352039
Chemical Formula
C20H19FN6O2
Synonyms
  • Nanatinostat
External IDs
  • CHR-3996

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Nanatinostat.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Nanatinostat.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Nanatinostat.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Nanatinostat.
VorinostatThe risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Nanatinostat is combined with Vorinostat.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
YTL7A418KQ
CAS number
1256448-47-1
InChI Key
QRGHOAATPOLDPF-VQFNDLOPSA-N
InChI
InChI=1S/C20H19FN6O2/c21-13-2-4-17-11(5-13)1-3-14(25-17)8-22-18-15-9-27(10-16(15)18)20-23-6-12(7-24-20)19(28)26-29/h1-7,15-16,18,22,29H,8-10H2,(H,26,28)/t15-,16+,18+
IUPAC Name
2-[(1R,5S,6R)-6-{[(6-fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-N-hydroxypyrimidine-5-carboxamide
SMILES
ONC(=O)C1=CN=C(N=C1)N1C[C@H]2[C@@H](C1)[C@@H]2NCC1=NC2=CC=C(F)C=C2C=C1

References

General References
Not Available
ChemSpider
26632319
BindingDB
50347385
ChEMBL
CHEMBL1801250
ZINC
ZINC000101424935

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2RecruitingTreatmentEBV Associated Lymphoma / EBV Related Hodgkin's Lymphoma / EBV Related Non-Hodgkin's Lymphoma / EBV Related PTCL, Nos / EBV-Positive DLBCL, Nos / Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) / Epstein-Barr Virus-Associated Lymphoproliferative Disorder / Extranodal NK/T Cell Lymphoma1
1CompletedTreatmentTumors, Solid1
1, 2RecruitingTreatmentDisorders, Lymphoproliferative / Epstein-Barr virus associated lymphoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0734 mg/mLALOGPS
logP1.25ALOGPS
logP0.5ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)8.89ChemAxon
pKa (Strongest Basic)8.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area103.27 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity104.15 m3·mol-1ChemAxon
Polarizability40.64 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 15:28 / Updated on February 21, 2021 18:55